Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Share-based Compensation (2023 - 2025)

Immunocore Holdings' Share-based Compensation history spans 3 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 3.78% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $37.7 million, up 10.26%, while the annual FY2025 figure was $37.7 million, 10.26% up from the prior year.
  • Share-based Compensation for Q4 2025 was $8.3 million at Immunocore Holdings, down from $9.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.0 million in Q2 2025 and bottomed at $6.6 million in Q3 2024.
  • The 3-year median for Share-based Compensation is $8.7 million (2023), against an average of $8.7 million.
  • The largest annual shift saw Share-based Compensation dropped 20.0% in 2024 before it soared 49.98% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $7.2 million in 2023, then increased by 20.53% to $8.7 million in 2024, then decreased by 3.78% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Share-based Compensation are $8.3 million (Q4 2025), $9.8 million (Q3 2025), and $10.0 million (Q2 2025).